| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.34 | 0.005 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.006 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.006 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.09 | 0.007 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | -0.45 | 0.009 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.093 | 0.009 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |